A randomized phase II trial comparing weekly taxotere plus prednisolone versus prednisolone alone in androgen-independent prostate cancer

Frontiers of Radiation Therapy and Oncology

Volumn 41, Issue , 2008, Pages 108-116

  Fossa S D ^a,b  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; PREDNISOLONE; PROSTATE SPECIFIC ANTIGEN; TAXOID;

AGED; BLOOD; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFECT; HUMAN; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; MORTALITY; PHASE 2 CLINICAL TRIAL; PROSTATE TUMOR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PREDNISOLONE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUALITY OF LIFE; TAXOIDS;

EID: 49449085813     PISSN: 00719676     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000139885     Document Type: Conference Paper

References (16)

1. Clarke NW, Wylie JP: Chemotherapy in hormone refractory prostate cancer: where do we stand? Eur Urol 2004;46:709-711.
2. Fosså SD, Slee PH, Brausi M, et al: Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European Organization for Research and Treatment of Cancer Genitourinary Group. J Clin Oncol 2001;19:62-71.
3. Beer TM, Pierce WC, Lowe BA, Henner WD: Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann Oncol 2001;12;1273-1279.
4. Berry W, Dakhil S, Gregurich MA, Asmar L: Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin Oncol 2001;28(suppl 15);8-15.
5. Tannock IF, de Wit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-1512.
6. Petrylak DP, Tangen CM, Hussain MHA, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-1520.
7. Fosså SD, Jacobsen AB, Ginman C, et al: Weekly taxotere and prednisolone versus prednisolone alone in androgen-independent prostate cancer: a randomized phase II study. Eur Urol 2007;52:1691-1698.
8. Bubley GJ, Carducci M, Dahut W, et al: Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999;17:3461-3467.
9. Hedlund PO, Ala-Opas M, Brekkan E, et al: Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer. Scand J Urol Nephrol 2002;36:405-413.
10. Aaronson NK, Ahmedzai S, Bergman B, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: a quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-376.
11. Osoba D, Rodrigues G, Myles J, et al: Interpreting the significance of changes in health-related quality of life scores. J Clin Oncol 1998;16:139-144.
12. Fizazi K, Thuret R, Theodore C, et al: Early PSA rise subsequently followed by PSA decline is a common event in prostate cancer patients responders to chemotherapy. Ann Oncol 2004;15(suppl 3):427.
13. Fosså SD, Vaage S, Letocha H, Iversen J, Risberg T, Johannessen DC, Paus E, Smedsrud T: Liposomal doxorubicin (Caelyx®) in symptomatic androgen-independent prostate cancer (AIPC): delayed response and flare phenomenon should be considered. Scand J Urol Nephrol 2002;36:34-39.
14. Coleman RE, Major P, Lipton A, et al: Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005;23:4925-4935.
15. Cella D, Petrylak DP, Fishman M, et al: Role of quality of life in men with metastatic hormone-refractory prostate cancer: how does atrasentan influence quality of life? Eur Urol 2006;49:781-789.
16. Klein GL, Bi LX, Sherrard DJ, et al: Evidence supporting a role of glucocorticoids in short-term bone loss in burned children. Osteoporos Int 2004;15:468-474.